🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of the Prevalence of Endometriosis and Adenomyosis

Recruitingn/aAges 29 Years - 37 YearsFemaleAssistance Publique - Hôpitaux de Paris
NCT06211569 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Our study aims to assess the prevalence of adenomyosis and endometriosis in patients consulting for elective fertility preservation through the diagnosis of these pathologies by transvaginal pelvic ultrasound. Imaging data will be compared with clinical data (patient characteristics, clinical symptoms) as well as the assessment of anxiety, depression, and quality of life collected from the women.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Woman aged between 29 and 37 * Consultant for non-medical fertility preservation in the Reproductive Medicine Unit Port Royal, Cochin * Informed and not opposed to this research * Affiliated to a social security scheme Exclusion Criteria: * Pregnant women * Refusing to take part in the study * Under court protection, curatorship or guardianship * Women with a known malformation of the genital tract
💊

What it tests

  • Usual follow-up
📍

Where

1 site
Gynécologie Obstétrique II et médecine de la reproduction, Hôpital Cochin, Port Royal
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy